Innovative Therapies and Management of Complications in Hemoglobinopathies
A special issue of Thalassemia Reports (ISSN 2039-4365). This special issue belongs to the section "Innovative Treatment of Thalassemia".
Deadline for manuscript submissions: closed (31 May 2025) | Viewed by 1994
Special Issue Editors
Interests: thalassemia and sickle cell disease; complications; transfusion medicine; infections; molecular issues of haemo-globinopathies; adverse reactions and other complications of transfusiondpendent thalassaemia; patient blood management; blood donor management; pathogen reduction technologies; transfusion transmitted infections
Interests: transfusion medicine; clinical practices; quality and safety issues; regulatory issues; transfusion education for medical and nursing staff; haemovigilance; epidemiology; blood transfusion in the context of thalassaemia and sickle cell disease; molecular issues of haemoglobinopathies; adverse reactions and other complications of transfusion-dependent thalassaemia; patient blood management; risk management: an important tool for improving quality; blood donor management; pathogen reduction technologies; pathogen inactivation technologies; transfusion transmitted infections; surveillance for substances of human origin (SoHOs): blood, tissues, cells, medically assisted reproduction
Interests: thalassemia and sickle cell disease; complications; transfusion medicine; infections
Interests: thalassemia and sickle cell disease; complications; transfusion medicine; infections; pediatrics
Special Issue Information
Dear Colleagues,
Hemoglobinopathies, such as thalassemia and sickle cell disease, are common genetic disorders that constitute a major healthcare challenge worldwide. Advances in treatments and management strategies, particularly for complications such as transfusional iron overload and secondary iron overload, have improved patient outcomes. However, gaps remain in the management of emerging complications, including hepatocellular carcinoma, cardiovascular issues, and alloimmunization. The aim of this Special Issue is to explore cutting-edge therapies encompassing gene therapy, innovative iron chelation, and pharmacological approaches to improve the management of hemoglobinopathies.
This Special Issue will concentrate on comprehensive strategies for the management of transfusion-related complications and chronic issues that arise, with a focus on long-term patient survival. These will also include multidisciplinary care, early recognition of complications, and improving the safety of blood transfusions. Topics of interest comprise novel therapeutic interventions, long-term monitoring of iron overload, and personalized transfusion protocols to optimize patient outcomes.
Aimed at hematologists, clinical researchers, and allied health professionals, this Special Issue invites original research, systematic reviews, and case reports that bridge the gap between clinical practice and advanced research. It aims to advance knowledge and standards of care for patients with hemoglobinopathies, with an emphasis on improving quality of life and innovative, patient-centered management.
Dr. Sophia Delicou
Prof. Dr. Constantina Politis
Guest Editors
Dr. Aikaterini Xydaki
Dr. Maria Moraki
Guest Editor Assistants
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Thalassemia Reports is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hemoglobinopathies
- thalassemia
- sickle cell disease
- transfusion medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
